OBJECTIVE: To evaluate hepatic changes due to the use of enoxaparin for prophylaxis of deep vein thrombosis in patients submitted to total hip arthroplasty. METHODS: Thirty two patients submitted to elective total hip arthroplasty, using enoxaparin, were followed up for 65 days with serial doses of hepatic enzymes. RESULTS: Laboratory changes were found in up to 75% of patients during the study, which normalized after suspension of the treatment. No clinical evidence of hepatic lesion was found. CONCLUSION: Increase in hepatic enzymes levels occurs in most patients using enoxaparin, but without clinical relevance, and normalizes after suspension of the treatment.
Enoxaparin; Arthroplasty, replacement, hip; Hepatic insufficiency; Venous thrombosis
